Edgepark adds two CGMs to portfolio 

TWINSBURG, Ohio – Edgepark has expanded its portfolio to include the latest innovations from diabetes manufacturers, including a glucose biosensor that can be purchased without a prescription and a yearlong continuous glucose monitor system. "Our goal is to meet patients where they are in their health journey," said Anthony Alvarez, SVP and GM of Edgepark. "Diabetes is one of the fastest-growing conditions in the United States, and the introduction of innovations like (these) will no doubt play a pivotal role in the well-being of the patients we serve."  

Dexcom Stelo Glucose Biosensor System (Stelo) 

Edgepark is now one of a limited number of suppliers to offer the Dexcom Stelo, the first-ever FDA-cleared, over-the-counter glucose biosensor. This biosensor expands access to this technology to adults not on insulin and who don't have a history of problematic hypoglycemia. This accessibility, coupled with the ability to provide glucose insights directly to a smartphone without fingersticks, empowers a wider population to proactively understand and manage their metabolic health, the company says. This product is FSA/HSA eligible and can be ordered without a prescription from a health care provider here. 

"While CGMs have become more accessible through insurance in recent years, there are still many people who do not qualify for coverage – that's where over-the-counter options like the Stelo biosensor come into play," said Alvarez. "At Edgepark, we are laser-focused on overcoming accessibility challenges to help patients manage overall health and make more proactive decisions throughout their day." 

Eversense 365 Continuous Glucose Monitoring 

Edgepark is also offering the Eversense 365, the first and only FDA-cleared one-year implantable CGM system, intended for use in those living with Type 1 or Type 2 diabetes who are 18 and older. This product is inserted only once a year into the upper arm by a health care provider to provide continuous monitoring for 365 days.